drugset / Trial / NCT01405911

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

NCT01405911

Phase 2 Completed 242 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using diet and exercise therapy.

Timeline

Start
2011-08-16
Primary completion
2012-04-09
Completion
2012-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 25 mg Oral
Subject Sitagliptin Small molecule 50 mg Oral

Indications